Exclusion due to adverse event [Design Issues]

posted by Loky do – Egypt, 2021-03-29 17:59 (1904 d 12:18 ago) – Posting: # 22297
Views: 5,300

Dears

If subject during bioequivalence study suffered from diarrhea before 2 median Tmax of immediate-release drug product, in this case, the optimum action to be done to exclude the subject from the study after the event directly? or subject continues the study and excludes his results from the calculations if his plasma concentration-time profile is unreliable?

Thanks in advance


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
121 visitors (0 registered, 121 guests [including 17 identified bots]).
Forum time: 06:17 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5